Supriya Lifescience IPO Price Band Is 265 To 274 Rupees Know Gray Market Price And All The Details

Supriya Lifescience IPO: The Initial Public Offering (IPO) of Active Pharmaceuticals Ingredients ie API manufacturer Supriya Lifescience has opened for subscription from today. The company has fixed the price band for IPO at Rs 265-274 per share. Offer will close on 20th December. The company is planning to raise Rs 700 crore through its public offer. There is a strong demand for the pharma company in the gray market and this upper price band is trading at a premium of 91 per cent.

The company plans to raise Rs 700 crore through its public issue. Out of this, shares worth Rs 200 crore have been issued and also includes offer for sale of shares worth Rs 500 crore by promoter Satish Waman Wagh. Promoter Satish Waman Wagh holds 99.98 per cent equity shareholding in Supriya Lifesciences. The book running lead managers of the issue are ICICI Securities and Axis Capital.

read this also

Check Bounce Penalty Rules: There is a penalty for a check bounce, there is a provision for punishment, know what are the rules

Bank Strike Today: There will be problem in getting any work related to banks, bank employees strike today and on December 17

Bumper demand in gray market

Supriya Lifesciences has tremendous demand in the gray market. Against the issue price of Rs 274, it is priced at Rs 524 in the gray market with a premium of Rs 250 or 91.2 per cent.

Here is the lot size

Investors can bid for a minimum of 54 equity shares and thereafter in multiples of 54 shares. Retail investors can bid for a minimum of Rs 14,796 shares per lot and their maximum investment will be Rs 1,92,348 for 13 lots, as they are allowed to invest up to Rs 2 lakh in the IPO.

Of the total offer size, 75 per cent is reserved for Qualified Institutional Buyers (QIBs), 10 per cent for retail investors and the remaining 15 per cent for non-institutional investors.

this is the strategy

The company will utilize the fresh issue proceeds for capital expenditure requirements and loan repayment, in addition to general corporate purposes. As of October 2021, the company has a product line of 38 Active Pharmaceuticals Ingredients (APIs) focused on the therapeutic sector such as Antihistamines, Analgesics, Anesthetics, Vitamins, Anti-Asthma and Antiallergics.

It has consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing 45-50 per cent and 60-65 per cent respectively to API exports from India between FY 2017 and 2021. It was also one of the largest exporters of Salbutamol Sulphate to India, contributing 31 per cent of API exports from India in terms of volume in FY2011.


(This is an auto-generated article from syndicated news feed. TEAM BEPINKU.COM may not have modified or edited the article).

About the Author: TEAM BEPINKU.COM

We share trending news and latest information on Business, Technology, Entertainment, Politics, Sports, Automobiles, Education, Jobs, Health, Lifestyle, Travel and more. That's our work. We are a team led by Mahammad Sakil Ansari.

You May Also Like